Nyxoah Q4 Revenue Expected to Surge 348%, Full-Year Revenue Up 122%

martes, 13 de enero de 2026, 2:36 am ET1 min de lectura
NYXH--

Nyxoah SA expects Q4 revenue to rise 348% and full-year revenue to rise 122%, excluding deferred revenue deductions. The company's Genio system, a mask-free implantable device for Obstructive Sleep Apnea, received FDA approval in August 2025 and has established a strong foundation for sustained growth. NYXH's stock jumped 3.94% in after-hours trading.

Nyxoah Q4 Revenue Expected to Surge 348%, Full-Year Revenue Up 122%

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios